VIP and PACAP receptors in GtoPdb v.2023.1

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Vasoactive Intestinal Peptide Receptors [65, 66]) are activated by the endogenous peptides VIP, PACAP-38, PACAP-27, peptide histidine isoleucineamide (PHI), peptide histidine methionineamide (PHM) and peptide histidine valine (PHV). VPAC1 and VPAC2 receptors display comparable affinity for the PACAP peptides, PACAP-27 and PACAP-38, and VIP, whereas PACAP-27 and PACAP-38 are >100 fold more potent than VIP as agonists of most isoforms of the PAC1 receptor. However, one splice variant of the human PAC1 receptor has been reported to respond to PACAP-38, PACAP-27 and VIP with comparable affinity [30]. PG 99-465 [117] has been used as a selective VPAC2 receptor antagonist in a number of physiological studies, but has been reported to have significant activity at VPAC1 and PAC1 receptors [36]. The selective PAC1 receptor agonist maxadilan, was extracted from the salivary glands of sand flies (Lutzomyia longipalpis) and has no sequence homology to VIP or the PACAP peptides [118]. Two deletion variants of maxadilan, M65 [183] and Max.d.4 [119] have been reported to be PAC1 receptor antagonists, but these peptides have not been extensively characterised.

[1]  Hantao Liu,et al.  PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache? , 2020, Pain.

[2]  Peter Buneman,et al.  Why data citation isn't working, and what to do about it , 2020, Database J. Biol. Databases Curation.

[3]  L. Edvinsson,et al.  PACAP38 and PAC1 receptor blockade: a new target for headache? , 2018, The Journal of Headache and Pain.

[4]  J. Waschek,et al.  VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage , 2016, Journal of Neuroinflammation.

[5]  O. Hubscher,et al.  Monocytes from Sjögren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis , 2014, Clinical and experimental immunology.

[6]  S. Qureshi,et al.  Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes. , 2012, Journal of medicinal chemistry.

[7]  H. Vaudry,et al.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide: IUPHAR Review 1 , 2012, British journal of pharmacology.

[8]  D. Thedens,et al.  Characterization of Intestinal and Pancreatic Dysfunction in VPAC1-Null Mutant Mouse , 2011, Pancreas.

[9]  J. Sebat,et al.  Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia , 2011, Nature.

[10]  H. Xu,et al.  Crystal Structure of the PAC1R Extracellular Domain Unifies a Consensus Fold for Hormone Recognition by Class B G-Protein Coupled Receptors , 2011, PloS one.

[11]  I. Gozes.  NAP (davunetide) provides functional and structural neuroprotection. , 2011, Current pharmaceutical design.

[12]  M. Tanida,et al.  PACAP centrally mediates emotional stress-induced corticosterone responses in mice , 2011, Stress.

[13]  H. Piggins.  Schizophrenia: Zooming in on a gene , 2011, Nature.

[14]  J. Hannibal,et al.  Localisation of the neuropeptide PACAP and its receptors in the rat parathyroid and thyroid glands. , 2011, General and comparative endocrinology.

[15]  Jianxin Shi,et al.  Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. , 2011, The American journal of psychiatry.

[16]  H. Hsiung,et al.  Temporal Phasing of Locomotor Activity, Heart Rate Rhythmicity and Core Body Temperature Is Disrupted in Vip Receptor 2 (vpac2) Deficient Mice. Runnning Title: Disrupted Circadian Phasing in Vpac2 Deficient Mice , 2022 .

[17]  B. Bradley,et al.  Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor , 2011, Nature.

[18]  A. Campagnoni,et al.  Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis , 2010, Proceedings of the National Academy of Sciences.

[19]  W. Falls,et al.  Roles for Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Expression and Signaling in the Bed Nucleus of the Stria Terminalis (BNST) in Mediating the Behavioral Consequences of Chronic Stress , 2010, Journal of Molecular Neuroscience.

[20]  J. Armstrong,et al.  Circadian Control of Mouse Heart Rate and Blood Pressure by the Suprachiasmatic Nuclei: Behavioral Effects Are More Significant than Direct Outputs , 2010, PloS one.

[21]  L. Eiden,et al.  Stress hormone synthesis in mouse hypothalamus and adrenal gland triggered by restraint is dependent on pituitary adenylate cyclase-activating polypeptide signaling , 2010, Neuroscience.

[22]  D. Bechtold,et al.  PACAP Neurons in the Hypothalamic Ventromedial Nucleus Are Targets of Central Leptin Signaling , 2009, The Journal of Neuroscience.

[23]  A. Harmar,et al.  The Neurotransmitter VIP Expands the Pool of Symmetrically Dividing Postnatal Dentate Gyrus Precursors via VPAC2 Receptors or Directs Them Toward a Neuronal Fate via VPAC1 receptors , 2009, Stem cells.

[24]  J. Waschek,et al.  Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis , 2009, Proceedings of the National Academy of Sciences.

[25]  J. Hannibal,et al.  Mice lacking the PACAP type I receptor have impaired photic entrainment and negative masking. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[26]  A. Couvineau,et al.  Class-B GPCR activation: is ligand helix-capping the key? , 2008, Trends in biochemical sciences.

[27]  M. Jarvis,et al.  Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R). , 2008, Bioorganic & medicinal chemistry letters.

[28]  D. Bechtold,et al.  Metabolic rhythm abnormalities in mice lacking VIP-VPAC2 signaling. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[29]  A. Couvineau,et al.  Class II G protein-coupled receptors for VIP and PACAP: Structure, models of activation and pharmacology , 2007, Peptides.

[30]  P. Hajduk,et al.  Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS , 2007, Proceedings of the National Academy of Sciences.

[31]  J. Mcculloch,et al.  A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology , 2006, Neuropharmacology.

[32]  C. McCaig,et al.  Expression of the human PAC1 receptor leads to dose-dependent hydrocephalus-related abnormalities in mice. , 2006, The Journal of clinical investigation.

[33]  Inbar Pilzer,et al.  A Splice Variant to PACAP Receptor That Is Involved in Spermatogenesis Is Expressed in Astrocytes , 2006, Annals of the New York Academy of Sciences.

[34]  A. Couvineau,et al.  Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor , 2006, Journal of Biological Chemistry.

[35]  Javier Martín,et al.  Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. , 2006, The American journal of pathology.

[36]  P. Gressens,et al.  VPAC2 Receptors Mediate Vasoactive Intestinal Peptide-Induced Neuroprotection against Neonatal Excitotoxic Brain Lesions in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[37]  Erik D Herzog,et al.  Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons , 2005, Nature Neuroscience.

[38]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide prevents the effects of ceramides on migration, neurite outgrowth, and cytoskeleton remodeling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Jensen,et al.  VIP Attenuation of the Severity of Experimental Pancreatitis Is Due to VPAC1 Receptor-Mediated Inhibition of Cytokine Production , 2005, Pancreas.

[40]  M. Brede,et al.  Pulmonary Hypertension and Right Heart Failure in Pituitary Adenylate Cyclase–Activating Polypeptide Type I Receptor–Deficient Mice , 2004 .

[41]  C. Colwell,et al.  Selective deficits in the circadian light response in mice lacking PACAP. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[42]  E. Goetzl,et al.  A Natural Variant Type II G Protein-coupled Receptor for Vasoactive Intestinal Peptide with Altered Function* , 2004, Journal of Biological Chemistry.

[43]  R. Riek,et al.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Matsumura,et al.  Development / Plasticity / Repair Pituitary Adenylate Cyclase-Activating Polypeptide Is Required for the Development of Spinal Sensitization and Induction of Neuropathic Pain , 2004 .

[45]  S. Rattan,et al.  The multiple mediators of neurogenic smooth muscle relaxation , 2004, Trends in Endocrinology & Metabolism.

[46]  K. Yamagata,et al.  Overexpression of Pituitary Adenylate Cyclase-Activating Polypeptide in Islets Inhibits Hyperinsulinemia and Islet Hyperplasia in Agouti Yellow Mice , 2004, Journal of Pharmacology and Experimental Therapeutics.

[47]  D. Cutler,et al.  Aberrant Gating of Photic Input to the Suprachiasmatic Circadian Pacemaker of Mice Lacking the VPAC2 Receptor , 2004, Journal of Neuroscience.

[48]  C. Martínez,et al.  Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. , 2004, Rheumatology.

[49]  A. Harmar,et al.  Distribution of the VPAC2 receptor in peripheral tissues of the mouse. , 2004, Endocrinology.

[50]  H. Hashimoto,et al.  Impaired long-term potentiation in vivo in the dentate gyrus of pituitary adenylate cyclase-activating polypeptide (PACAP) or PACAP type 1 receptor-mutant mice , 2003, Neuroreport.

[51]  C. Colwell,et al.  Disrupted circadian rhythms in VIP- and PHI-deficient mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[52]  J. Hannibal,et al.  Light‐induced phase shift in the Syrian hamster (Mesocricetus auratus) is attenuated by the PACAP receptor antagonist PACAP6‐38 or PACAP immunoneutralization , 2003, The European journal of neuroscience.

[53]  K. Nagai,et al.  Changes in light-induced phase shift of circadian rhythm in mice lacking PACAP. , 2003, Biochemical and biophysical research communications.

[54]  D. Pozo.  VIP- and PACAP-mediated immunomodulation as prospective therapeutic tools. , 2003, Trends in molecular medicine.

[55]  H. Vaudry,et al.  Pituitary adenylate cyclase‐activating polypeptide prevents C2‐ceramide‐induced apoptosis of cerebellar granule cells , 2003, Journal of neuroscience research.

[56]  H. Aihara,et al.  Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. , 2003, Diabetes.

[57]  M. Delgado,et al.  Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. , 2003, Gastroenterology.

[58]  P. Sexton,et al.  Novel Receptor Partners and Function of Receptor Activity-modifying Proteins* , 2003, The Journal of Biological Chemistry.

[59]  E. Goetzl,et al.  Roles of Vasoactive Intestinal Peptide (VIP) in the Expression of Different Immune Phenotypes by Wild-Type Mice and T Cell-Targeted Type II VIP Receptor Transgenic Mice1 , 2003, The Journal of Immunology.

[60]  Sanbing Shen,et al.  The mouse VPAC2 receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptide in vitro , 2003, The European journal of neuroscience.

[61]  E. Lerner,et al.  Maxadilan activates PAC1 receptors expressed in Xenopus laevis xelanophores. , 2002, Pigment cell research.

[62]  E. Goetzl,et al.  Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide , 2002, Regulatory Peptides.

[63]  A. Couvineau,et al.  Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP , 2002, Regulatory Peptides.

[64]  H. Hsiung,et al.  Vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating peptide receptor 2 deficiency in mice results in growth retardation and increased basal metabolic rate. , 2002, Endocrinology.

[65]  S. Shibata,et al.  Pituitary adenylate cyclase-activating polypeptide produces a phase shift associated with induction of mPer expression in the mouse suprachiasmatic nucleus , 2002, Neuroscience.

[66]  E. Maywood,et al.  The VPAC2 Receptor Is Essential for Circadian Function in the Mouse Suprachiasmatic Nuclei , 2002, Cell.

[67]  B. Ahrén,et al.  The neuropeptide PACAP contributes to the glucagon response to insulin-induced hypoglycaemia in mice. , 2002, Acta physiologica Scandinavica.

[68]  H. Vaudry,et al.  PACAP protects cerebellar granule neurons against oxidative stress‐induced apoptosis , 2002, The European journal of neuroscience.

[69]  C. Pan,et al.  A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes. , 2002, Diabetes.

[70]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[71]  H. Vaudry,et al.  Identification of a potential receptor for both peptide histidine isoleucine and peptide histidine valine. , 2002, Endocrinology.

[72]  R. Jensen,et al.  (N-stearyl, norleucine17) VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist , 2002, Journal of Molecular Neuroscience.

[73]  M. Delgado,et al.  Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[74]  W. Young,et al.  Pituitary adenylate cyclase-activating polypeptide is a sympathoadrenal neurotransmitter involved in catecholamine regulation and glucohomeostasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Anthony J Harmar,et al.  Family-B G-protein-coupled receptors , 2001, Genome Biology.

[76]  E. Goetzl,et al.  Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC2 receptor for vasoactive intestinal peptide , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[77]  E. Goetzl,et al.  Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[78]  R. Maldonado,et al.  Altered emotional behavior in PACAP-type-I-receptor-deficient mice. , 2001, Brain research. Molecular brain research.

[79]  A. Konnerth,et al.  Impairment of Mossy Fiber Long-Term Potentiation and Associative Learning in Pituitary Adenylate Cyclase Activating Polypeptide Type I Receptor-Deficient Mice , 2001, The Journal of Neuroscience.

[80]  M. Kanje,et al.  Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor , 2001, Neuroreport.

[81]  F. Jamen,et al.  Dissociation between Light-Induced Phase Shift of the Circadian Rhythm and Clock Gene Expression in Mice Lacking the Pituitary Adenylate Cyclase Activating Polypeptide Type 1 Receptor , 2001, The Journal of Neuroscience.

[82]  M. Johnson,et al.  ADP-ribosylation factor-dependent phospholipase D activation by VPAC receptors and a PAC(1) receptor splice variant. , 2001, Molecular pharmacology.

[83]  J. Habener,et al.  Novel Alternatively Spliced Exon in the Extracellular Ligand-binding Domain of the Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Type 1 Receptor (PAC1R) Selectively Increases Ligand Affinity and Alters Signal Transduction Coupling during Spermatogenesis* , 2001, The Journal of Biological Chemistry.

[84]  M. Johnson,et al.  Mechanisms of phospholipase C activation by the vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 receptor. , 2001, Endocrinology.

[85]  J. Reubi.  In Vitro Evaluation of VIP/PACAP Receptors in Healthy and Diseased Human Tissues: Clinical Implications , 2000, Annals of the New York Academy of Sciences.

[86]  J. Pisegna,et al.  Essential Structural Motif in the C‐Terminus of the PACAP Type I Receptor for Signal Transduction and Internalization , 2000, Annals of the New York Academy of Sciences.

[87]  H. Vaudry,et al.  The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[88]  H. Marston,et al.  Overexpression of the human VPAC2 receptor in the suprachiasmatic nucleus alters the circadian phenotype of mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[89]  A Fournier,et al.  Comparative distribution of pituitary adenylate cyclase‐activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development , 2000, The Journal of comparative neurology.

[90]  P. Robberecht,et al.  Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor , 2000, Peptides.

[91]  D. Reglodi,et al.  Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. , 2000, Stroke.

[92]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. , 2000, Pharmacological reviews.

[93]  J C Reubi,et al.  Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. , 2000, Cancer research.

[94]  J. Bockaert,et al.  PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. , 2000, The Journal of clinical investigation.

[95]  M. Kanje,et al.  Alteration of PACAP distribution and PACAP receptor binding in the rat sensory nervous system following sciatic nerve transection , 2000, Brain Research.

[96]  R. Hauger,et al.  N‐Terminal Splice Variants of the Type I PACAP Receptor: Isolation, Characterization and Ligand Binding/Selectivity Determinants , 1999, Journal of neuroendocrinology.

[97]  P. de Neef,et al.  Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands. , 1999, Molecular pharmacology.

[98]  S. Denda,et al.  Functional Characterization of Structural Alterations in the Sequence of the Vasodilatory Peptide Maxadilan Yields a Pituitary Adenylate Cyclase-activating Peptide Type 1 Receptor-specific Antagonist* , 1999, The Journal of Biological Chemistry.

[99]  H. Vaudry,et al.  Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[100]  S. Fleetwood-Walker,et al.  VIP and PACAP: very important in pain? , 1999, Trends in pharmacological sciences.

[101]  M. Shibanuma,et al.  Pituitary adenylate cyclase-activating polypeptide receptors during development: expression in the rat embryo at primitive streak stage , 1999, Neuroscience.

[102]  N. Copeland,et al.  Genomic organization and chromosomal location of the mouse vasoactive intestinal polypeptide 1 (VPAC1) receptor. , 1999, Genomics.

[103]  P. Gressens,et al.  Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives. , 1999, The Journal of pharmacology and experimental therapeutics.

[104]  P. Robberecht,et al.  The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy , 1999, Neuropharmacology.

[105]  P. Robberecht,et al.  Analogues of VIP, Helodermin, and PACAP Discriminate between Rat and Human VIP1 and VIP2 Receptors a , 1998, Annals of the New York Academy of Sciences.

[106]  I. Tatsuno,et al.  Maxadilan Is a Specific Agonist and Its Deleted Peptide (M65) Is a Specific Antagonist for PACAP Type 1 Receptor , 1998, Annals of the New York Academy of Sciences.

[107]  P. de Neef,et al.  Influence of selective VIP receptor agonists in the rat gastric fundus. , 1998, European journal of pharmacology.

[108]  A. Copp,et al.  Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. , 1998, Brain research. Developmental brain research.

[109]  E. Carpenter,et al.  Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[110]  J. Hannibal,et al.  Expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the postnatal and adult rat cerebellar cortex , 1998, Neuroreport.

[111]  P. de Neef,et al.  Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors. , 1998, European journal of pharmacology.

[112]  J. Waschek,et al.  Differential Effects of Peptide Histidine Isoleucine (PHI) and Related Peptides on Stimulation and Suppression of Neuroblastoma Cell Proliferation , 1998, The Journal of Biological Chemistry.

[113]  S. Rawlings,et al.  International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. , 1998, Pharmacological reviews.

[114]  P. Gressens,et al.  Involvement of Pituitary Adenylate Cyclase‐Activating Polypeptide II Vasoactive Intestinal Peptide 2 Receptor in Mouse Neocortical Astrocytogenesis , 1998, Journal of neurochemistry.

[115]  H. Vaudry,et al.  Localization, characterization, and second messenger coupling of pituitary adenylate cyclase-activating polypeptide receptors in the fetal human adrenal gland during the second trimester of gestation. , 1998, The Journal of clinical endocrinology and metabolism.

[116]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway , 1998, Neuroscience.

[117]  A. Couvineau,et al.  Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship. , 1998, The Journal of pharmacology and experimental therapeutics.

[118]  S. Schiffmann,et al.  Autoradiographic Visualization of the Receptor Subclasses for Vasoactive Intestinal Polypeptide (VIP) in Rat Brain , 1997, Peptides.

[119]  P. Robberecht,et al.  The Long-Acting Vasoactive Intestinal Polypeptide Agonist RO 25-1553 Is Highly Selective of the VIP2 Receptor Subclass , 1997, Peptides.

[120]  P. Robberecht,et al.  In Vitro Properties of a High Affinity Selective Antagonist of the VIP1 Receptor , 1997, Peptides.

[121]  P. Robberecht,et al.  Development of High Affinity Selective VIP1 Receptor Agonists , 1997, Peptides.

[122]  S. Shioda,et al.  Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain , 1997, Neuroscience Research.

[123]  P. Gressens,et al.  Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. , 1997, The Journal of clinical investigation.

[124]  C. Delporte,et al.  The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. , 1997, Biochimica et biophysica acta.

[125]  Y. Oiso,et al.  Regulation of the rat proopiomelanocortin gene expression in AtT-20 cells. II: Effects of the pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide. , 1997, Endocrinology.

[126]  E. Goetzl,et al.  Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. , 1997, The Journal of pharmacology and experimental therapeutics.

[127]  P. J. Larsen,et al.  Pituitary Adenylate Cyclase-Activating Peptide (PACAP) in the Retinohypothalamic Tract: A Potential Daytime Regulator of the Biological Clock , 1997, The Journal of Neuroscience.

[128]  H. Vaudry,et al.  Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts , 1997, Neuroscience.

[129]  J. Loeffler,et al.  PACAP type I receptor activation promotes cerebellar neuron survival through the cAMP/PKA signaling pathway. , 1997, DNA and cell biology.

[130]  E. Goetzl,et al.  Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. , 1997, American journal of respiratory cell and molecular biology.

[131]  E. Lerner,et al.  Maxadilan, the Vasodilator from Sand Flies, Is a Specific Pituitary Adenylate Cyclase Activating Peptide Type I Receptor Agonist* , 1997, The Journal of Biological Chemistry.

[132]  S. Said.  Vasoactive Intestinal Peptide and Nitric Oxide: Divergent Roles in Relation to Tissue Injury , 1996, Annals of the New York Academy of Sciences.

[133]  E. Goetzl,et al.  Changes in adhesion molecule expression during distinct patterns of immune cell migration in the inflamed lung. , 1996, Archives of histology and cytology.

[134]  P. de Neef,et al.  Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states. , 1996, Molecular pharmacology.

[135]  A. Harmar,et al.  Phospholipase C Activation by VIP1 and VIP2 Receptors Expressed in COS 7 Cells Involves a Pertussis Toxin‐Sensitive Mechanism , 1996, Annals of the New York Academy of Sciences.

[136]  S. Mojsov,et al.  Tissue Specific Expression of Different Human ReceptorTypes for Pituitary Adenylate Cyclase Activating Polypeptideand Vasoactive Intestinal Polypeptide: Implications fortheir Role in Human Physiology , 1996, Journal of neuroendocrinology.

[137]  S. Scherer,et al.  Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: a possible contributor to the holoprosencephaly 3 phenotype. , 1996, Genomics.

[138]  J. Bockaert,et al.  Alternative Splicing in the N-terminal Extracellular Domain of the Pituitary Adenylate Cyclase-activating Polypeptide (PACAP) Receptor Modulates Receptor Selectivity and Relative Potencies of PACAP-27 and PACAP-38 in Phospholipase C Activation* , 1996, The Journal of Biological Chemistry.

[139]  R. Shigemoto,et al.  Distribution of the mRNA for a pituitary adenylate cyclase‐activating polypeptide receptor in the rat brain: An in situ hybridization study , 1996, The Journal of comparative neurology.

[140]  M. Delgado,et al.  Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes , 1996, Journal of Neuroimmunology.

[141]  F. Sundler,et al.  Expression of pituitary adenylate cyclase activating peptide (PACAP) and PACAP type I receptors in the rat adrenal medulla , 1996, Regulatory Peptides.

[142]  F. Stivala,et al.  Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. , 1996, Molecular pharmacology.

[143]  H. Hashimoto,et al.  cDNA cloning of a mouse pituitary adenylate cyclase-activating polypeptide receptor. , 1996, Biochimica et biophysica acta.

[144]  D. Przywara,et al.  A Non-cholinergic Transmitter, Pituitary Adenylate Cyclase-activating Polypeptide, Utilizes a Novel Mechanism to Evoke Catecholamine Secretion in Rat Adrenal Chromaffin Cells * , 1996, The Journal of Biological Chemistry.

[145]  A. Couvineau,et al.  Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. , 1996, European journal of pharmacology.

[146]  S. Rawlings,et al.  Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. , 1996, Endocrine reviews.

[147]  T. Usdin,et al.  PACAP acts through VIP type 2 receptors in the rat testis , 1995, Neuropeptides.

[148]  H. Hashimoto,et al.  Structure of the gene encoding the mouse pituitary adenylate cyclase-activating polypeptide receptor. , 1995, Gene.

[149]  A. Harmar,et al.  The distribution of vasoactive intestinal peptide2 receptor messenger RNA in the rat brain and pituitary gland as assessed by in situ hybridization , 1995, Neuroscience.

[150]  N. Aiyar,et al.  Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor. , 1995, Biochemical and biophysical research communications.

[151]  E. Goetzl,et al.  Immunochemical localization of type I VIP receptor and NK-1-type substance P receptor in rat lung. , 1995, The American journal of physiology.

[152]  E. Goetzl,et al.  Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[153]  J. Vilardaga,et al.  Pharmacological properties of two recombinant splice variants of the PACAP type I receptor, transfected and stably expressed in CHO cells. , 1995, European journal of pharmacology.

[154]  F. Holsboer,et al.  Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor. , 1995, Biochemical Society transactions.

[155]  C. Delporte,et al.  Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide stimulate two signaling pathways in CHO cells stably transfected with the selective type I PACAP receptor , 1995, Molecular and Cellular Endocrinology.

[156]  S. Shioda,et al.  Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) and Its Receptors: Neuroendocrine and Endocrine Interaction , 1995, Frontiers in Neuroendocrinology.

[157]  J. Goossens,et al.  Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. , 1994, Biochemical and biophysical research communications.

[158]  T. Bonner,et al.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. , 1994, Endocrinology.

[159]  C. Szpirer,et al.  Chromosomal assignment of 11 loci in the rat by mouse-rat somatic hybrids and linkage , 1994, Mammalian Genome.

[160]  H. Vaudry,et al.  Ontogeny of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the rat cerebellum: a quantitative autoradiographic study. , 1994, Brain research. Developmental brain research.

[161]  M. Stoffel,et al.  Human type I pituitary adenylate cyclase activating polypeptide receptor (ADCYAP1R): localization to chromosome band 7p14 and integration into the cytogenetic, physical, and genetic map of chromosome 7. , 1994, Genomics.

[162]  R. Garippa,et al.  Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part I: In vitro and in vivo bronchodilator studies. , 1994, The Journal of pharmacology and experimental therapeutics.

[163]  R. Garippa,et al.  Ro 25-1553: a novel, long-acting vasoactive intestinal peptide agonist. Part II: Effect on in vitro and in vivo models of pulmonary anaphylaxis. , 1994, The Journal of pharmacology and experimental therapeutics.

[164]  E. Goetzl,et al.  Human vasoactive intestinal peptide1 receptors expressed by stable transfectants couple to two distinct signaling pathways. , 1994, Biochemical and biophysical research communications.

[165]  J. Miyazaki,et al.  Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[166]  M. Nakata,et al.  Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells. , 1994, The Journal of biological chemistry.

[167]  H. Onda,et al.  Molecular cloning and functional expression of a cDNA encoding a human pituitary adenylate cyclase activating polypeptide receptor. , 1993, Biochemical and biophysical research communications.

[168]  G. Fink,et al.  The VIP2 receptor: Molecular characterisation of a cDNA encoding a novel receptor for vasoactive intestinal peptide , 1993, FEBS letters.

[169]  H. Vaudry,et al.  Localization and characterization of PACAP receptors in the rat cerebellum during development: Evidence for a stimulatory effect of PACAP on immature cerebellar granule cells , 1993, Neuroscience.

[170]  G. Makhlouf,et al.  VIP-mediated G protein-coupled Ca2+ influx activates a constitutive NOS in dispersed gastric muscle cells. , 1993, The American journal of physiology.

[171]  Laurent Journot,et al.  Differential signal transduction by five splice variants of the PACAP receptor , 1993, Nature.

[172]  S. Wank,et al.  Molecular cloning and functional expression of the pituitary adenylate cyclase-activating polypeptide type I receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[173]  E. Goetzl,et al.  Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. , 1993, Biochemical and biophysical research communications.

[174]  P. Magistretti,et al.  Vasoactive intestinal peptide and noradrenaline exert long-term control on glycogen levels in astrocytes: blockade by protein synthesis inhibition , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[175]  P. de Neef,et al.  Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. , 1992, European journal of biochemistry.

[176]  R. Shigemoto,et al.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide , 1992, Neuron.

[177]  L. Buscail,et al.  The two forms of the pituitary adenylate cyclase activating polypeptide (PACAP (1–27) and PACAP (1–38)) interact with distinct receptors on rat pancreatic AR 4‐2J cell membranes , 1991, FEBS letters.

[178]  T. Görcs,et al.  Two high affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. , 1991, Endocrinology.

[179]  S. Said.  Vasoactive intestinal polypeptide biologic role in health and disease , 1991, Trends in Endocrinology & Metabolism.

[180]  S. Said,et al.  Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines , 1990, Peptides.

[181]  N. Minamino,et al.  Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). , 1990, Biochemical and biophysical research communications.

[182]  M. Culler,et al.  Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. , 1989, Biochemical and biophysical research communications.

[183]  S. Reichlin.  Neuroendocrine Significance of Vasoactive Intestinal Polypeptide a , 1988, Annals of the New York Academy of Sciences.

[184]  P. de Neef,et al.  A new type of functional VIP receptor has an affinity for helodermin in human SUP‐T1 lymphoblasts , 1988, FEBS letters.

[185]  R. Malhotra,et al.  Vasoactive intestinal polypeptide and muscarine mobilize intracellular Ca2+ through breakdown of phosphoinositides to induce catecholamine secretion. Role of IP3 in exocytosis. , 1988, The Journal of biological chemistry.

[186]  P. Hof,et al.  Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain , 1987, Neuroscience.

[187]  Y. Yiangou,et al.  Isolation, characterization, and pharmacological actions of peptide histidine valine 42, a novel prepro-vasoactive intestinal peptide-derived peptide. , 1987, The Journal of biological chemistry.

[188]  C. Ottaway.  Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. , 1987, Immunology.

[189]  W. Rostène,et al.  Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system , 1986, Brain Research.

[190]  L. Eiden,et al.  Vasoactive intestinal peptide and electrical activity influence neuronal survival. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[191]  H. Okamoto,et al.  Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27 , 1983, Nature.

[192]  L. Moroder,et al.  Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes , 1983, FEBS letters.

[193]  V. Mutt,et al.  Isolation and characterization of the intestinal peptide porcine PHI (PHI-27), a new member of the glucagon--secretin family. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[194]  M. Rousset,et al.  Vasoactive intestinal peptide: a potent stimulator of adenosine 3':5'-cyclic monophosphate accumulation in gut carcinoma cell lines in culture. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[195]  V. Mutt,et al.  Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. , 1972, European journal of biochemistry.

[196]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[197]  A. Couvineau,et al.  The family B1 GPCR: structural aspects and interaction with accessory proteins. , 2012, Current drug targets.

[198]  E. Goetzl,et al.  VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis. , 2011, Cellular immunology.

[199]  H. Vaudry,et al.  Pituitary Adenylate Cyclase-Activating Polypeptide Inhibits Food Intake in Mice Through Activation of the Hypothalamic Melanocortin System , 2009, Neuropsychopharmacology.

[200]  I. Gozes,et al.  VIP: Molecular biology and neurobiological function , 2007, Molecular Neurobiology.

[201]  A. Couvineau,et al.  VPAC receptors for VIP and PACAP. , 2002, Receptors & channels.

[202]  A. Couvineau,et al.  Vasoactive Intestinal Peptide (VIP)1 Receptor THREE NONADJACENT AMINO ACIDS ARE RESPONSIBLE FOR SPECIES SELECTIVITY WITH RESPECT TO RECOGNITION OF PEPTIDE HISTIDINE ISOLEUCINEAMIDE* , 1996 .

[203]  Y. Cai,et al.  Assignments of the genes for rat pituitary adenylate cyclase activating polypeptide (Adcyap1) and its receptor subtypes (Adcyap1r1, Adcyap1r2, and Adcyap1r3). , 1995, Cytogenetics and cell genetics.

[204]  K. Takahashi,et al.  Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. , 1993, The Journal of endocrinology.